NASDAQ:IMNN Imunon (IMNN) Stock Price, News & Analysis $0.72 -0.03 (-4.00%) (As of 11/15/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends About Imunon Stock (NASDAQ:IMNN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Imunon alerts:Sign Up Key Stats Today's Range$0.67▼$0.7650-Day Range$0.72▼$1.1452-Week Range$0.48▼$3.65Volume164,653 shsAverage Volume201,005 shsMarket Capitalization$10.45 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingStrong Buy Company OverviewImunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.Read More… Free Cheat Sheet: Build a Dividend Portfolio (Ad)Have you ever wanted to build your own, custom dividend portfolio? A well-rounded portfolio of high quality dividend stocks that produce passive cash flow is one of the best ways to build your nest egg. And, according to one expert, you can do it with a very straightforward process too!These FIVE (FREE) Dividend Investing Cheatsheets Show you How! Imunon Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks54th Percentile Overall ScoreIMNN MarketRank™: Imunon scored higher than 54% of companies evaluated by MarketBeat, and ranked 585th out of 970 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingImunon has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageImunon has only been the subject of 2 research reports in the past 90 days.Read more about Imunon's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Imunon are expected to grow in the coming year, from ($1.68) to ($1.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Imunon is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Imunon is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImunon has a P/B Ratio of 1.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Imunon's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.52% of the float of Imunon has been sold short.Short Interest Ratio / Days to CoverImunon has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Imunon has recently increased by 43.87%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImunon does not currently pay a dividend.Dividend GrowthImunon does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.52% of the float of Imunon has been sold short.Short Interest Ratio / Days to CoverImunon has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Imunon has recently increased by 43.87%, indicating that investor sentiment is decreasing significantly. News and Social Media3.0 / 5News Sentiment0.48 News SentimentImunon has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Imunon this week, compared to 1 article on an average week.Search Interest3 people have searched for IMNN on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows3 people have added Imunon to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Imunon insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.00% of the stock of Imunon is held by insiders.Percentage Held by InstitutionsOnly 4.47% of the stock of Imunon is held by institutions.Read more about Imunon's insider trading history. Receive IMNN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Imunon and its competitors with MarketBeat's FREE daily newsletter. Email Address IMNN Stock News HeadlinesHC Wainwright Lowers Imunon (NASDAQ:IMNN) Price Target to $12.00November 13, 2024 | americanbankingnews.comAnalysts Set Expectations for Imunon Q1 EarningsNovember 12, 2024 | americanbankingnews.comThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin conference in Nashville … Where he told an adoring crowd that the U.S. would become … “The crypto capital of the planet and the Bitcoin superpower of the world.”November 17, 2024 | Weiss Ratings (Ad)IMNN: Meeting with FDA in Preparation for Phase 3 Ovarian Cancer TrialNovember 11, 2024 | finance.yahoo.comImunon Inc (IMNN) Q3 2024 Earnings Call Highlights: Promising Clinical Advances Amid Financial ...November 8, 2024 | finance.yahoo.comImunon presents data from Phase 2 OVATION 2 clinical trialNovember 7, 2024 | markets.businessinsider.comImunon, Inc. (IMNN) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | seekingalpha.comImunon Announces Positive Data From Phase 2 Trial Of IMNN-001 In Advanced Ovarian Cancer, Stock DownNovember 7, 2024 | markets.businessinsider.comSee More Headlines IMNN Stock Analysis - Frequently Asked Questions How have IMNN shares performed this year? Imunon's stock was trading at $0.68 at the start of the year. Since then, IMNN shares have increased by 6.0% and is now trading at $0.7206. View the best growth stocks for 2024 here. How do I buy shares of Imunon? Shares of IMNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Imunon own? Based on aggregate information from My MarketBeat watchlists, some other companies that Imunon investors own include Meta Platforms (META), Advanced Micro Devices (AMD), Energy Transfer (ET), NVIDIA (NVDA), AT&T (T), AbbVie (ABBV) and Broadcom (AVGO). Company Calendar Today11/17/2024Fiscal Year End12/31/2024Next Earnings (Estimated)3/27/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMNN CUSIPN/A CIK749647 Webwww.imunon.com Phone(609) 896-9100Fax609-896-2200Employees33Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside+1,565.3%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,510,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-230.05% Return on Assets-128.98% Debt Debt-to-Equity RatioN/A Current Ratio2.30 Quick Ratio2.30 Sales & Book Value Annual Sales$500,000.00 Price / Sales20.90 Cash FlowN/A Price / Cash FlowN/A Book Value$0.56 per share Price / Book1.29Miscellaneous Outstanding Shares14,500,000Free Float13,776,000Market Cap$10.45 million OptionableNot Optionable Beta2.14 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:IMNN) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imunon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Imunon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.